Biotechnological production of sialylated solid lipid microparticles as inhibitors of influenza A virus infection
| Autor: | Emeline Richard, Aurélien Traversier, Thomas Julien, Manuel Rosa-Calatrava, Jean-Luc Putaux, Isabelle Jeacomine, Eric Samain |
|---|---|
| Přispěvatelé: | Centre de Recherches sur les Macromolécules Végétales (CERMAV), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), VirNext (VirNext), Faculté de Médecine RTH Laennec, ANR-17-EURE-0003,CBH-EUR-GS,CBH-EUR-GS(2017), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), PUTAUX, Jean-Luc |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
[SDV.BIO]Life Sciences [q-bio]/Biotechnology
Hemagglutinins Viral glycosides Hemagglutinin Glycoproteins Influenza Virus Biochemistry Lipids [SDV.BIO] Life Sciences [q-bio]/Biotechnology Influenza A Virus H1N1 Subtype glyco-engineering Influenza A virus [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Influenza Human [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases Humans solid lipid microparticles sialosides influenza viruses |
| Zdroj: | Glycobiology Glycobiology, 2022, ⟨10.1093/glycob/cwac054⟩ |
| ISSN: | 0959-6658 1460-2423 |
| DOI: | 10.1093/glycob/cwac054⟩ |
| Popis: | Influenza viruses bind to their target through a multivalent interaction of their hemagglutinins (HAs) with sialosides at the host cell surface. To fight the virus, one therapeutic approach consists in developing sialylated multivalent structures that can saturate the virus HAs and prevent the binding to host cells. We describe herein the biotechnological production of sialylated solid lipid microparticles (SSLMs) in 3 steps: (i) a microbiological step leading to the large-scale production of sialylated maltodextrins by metabolic engineering of an Escherichia coli strain, (ii) a new in vitro glycosylation process using the amylomaltase MalQ, based on the transglycosylation of the terminal sialoside ligand of the sialylated maltodextrin onto a long-chain alkyl glucoside, and (iii) the formulation of the final SSLMs presenting a multivalent sialic acid. We also describe the morphology and structure of the SSLMs and demonstrate their very promising properties as influenza virus inhibitors using hemagglutination inhibition and microneutralization assays on the human A/H1N1 pdm09 virus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|